Respiratory Conditions

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

The researchers identified 32 proteins associated with rapid declines in lung function.

The company recently announced promising results from its phase 2a clinical of an agent that the company says is the first to target Traf2- and NCK-interacting kinase, or TNIK for short.

The company said that it will submit a new drug application for the IPF drug, called nerandomilast, based on the positive results.

“Immunity debt” may be the explanation

A nomogram based on four pulmonary factors is helpful but not a substitute for clinical judgment, say the authors.

Pulmonary complications remain a major cause of morbidity and mortality in rheumatoid arthritis-associated interstitial lung disease, despite increasing research interest in the condition.

A new study conducted by researchers at the United Therapeutics Corporation in Durham, NC, looked to characterize PH-ILD disease burden by analyzing healthcare resource utilization (HCRU) and cost data.

USC researchers found a link between childhood exposure to nitrogen dioxide well below EPA limits and bronchitis symptoms in adults.

For patients with interstitial lung disease (ILD), a subsequent diagnosis of pulmonary hypertension substantially increases utilization of healthcare resources as well as costs.

Up until recently, no single study had validated the relationship between lung volume and tissue and static respiratory system compliance at the applied positive end-expiratory pressure.

A new study looked to show how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions can lead to a rare, lethal, genetic lung disease which causes respiratory failure in many newborns and infants.

Early efficacy data from a phase 2a safety trial on the subject was presented during an oral session at the American Thoracic Society 2024 International Conference in May.

A new study published May 2024 in Scientific Reports examined the changes in morphology and antibacterial activity in four honey varieties from Hungary matched against respiratory pathogens.

A new study published April 2024 in the JAMA Network looked to establish a link between burn pits and higher respiratory and cardiovascular disease in veterans, responding to widespread concern from veterans.

In 2022 alone, an estimated 10.6 million new TB cases were reported, mainly in low-income regions, highlighting the urgent need for further efforts in TB prevention and control.

Although chronic respiratory diseases remain the third leading cause of mortality, they have received less attention from the global community.

Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.

A new study points to disparities for patients in respiratory failure, which can have dire consequences. The lead researchers talk about the implications.

Airsupra is an anti-inflammatory rescue medication that can treat the symptoms of asthma while helping to prevent an attack.

Sotatercept is a first-in-class therapy to treat the rare disease pulmonary arterial hypertension. The FDA has assigned a target action date of March 26, 2024.

If approved, Ofev would be the first approved treatment for children and adolescents with fibrosing interstitial lung disease. A decision is expected in the fourth quarter of this year.

Tezspire is a biologic that specifically targets the inflammation associated with asthma.

Airsupra is the first rescue medication to manage both the symptoms and the inflammation associated with asthma.

Nirsevimab is a single-dose, long-acting antibody to protect infants from respiratory syncytial virus (RSV) lower respiratory tract infections. The FDA action date is in the third quarter of 2023.

If approved the vaccine, RSVpreF, would be available for people 60 years of age and older. The Prescription Drug User Fee Act goal date for a decision is in May 2023.

With this approval, about 300 children between 12 months and 24 months will be eligible for treatment with Orkambi.